Seattle Genetics Says Adcetris Sets New Standard In Frontline Lymphoma
The market for a new FDA-approved indication in frontline classical Hodgkin lymphoma could be worth $650m to $750m, some analysts say.
You may also be interested in...
VelosBio CEO: Series A Success Shows Investors Back His ADC Formula
VelosBio's well-backed Series A funding round showed that investors believe his team has identified the right combination of cancer target, linker and payload for creating a successful novel ADC, the biotech's CEO told Scrip.
Keeping Track: Ilumya, Adcetris Approved; Xtandi Priority Reviewed; Azedra Goal Date Extended
The latest drug development news and highlights from our US FDA Performance Tracker.
Seattle Genetics Looking To Improve, Replace Standards Of Care
Seattle Genetics is transitioning from a one-product to multi-product company while growing its established Adcetris franchise. New studies are coming for three additional antibody-drug conjugates aimed at solid tumors.